Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”

키워드

참고문헌 (8)

1. Hong H, "Letter : Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B : More questions than an answer-author’s reply", Clin Mol Hepatol, 30, pp.272~273 (2024)
2. Cheng PN, "Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B : More questions than an answer", Clin Mol Hepatol, 30, pp.144~146 (2024)
3. Lai RM, "Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients", World J Hepatol, 15, pp.964~972 (2023)
4. Jeong J, "Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients : A propensity score-matched analysis", Clin Mol Hepatol, 28, pp.254~264 (2022)
5. Shaheen AA, "Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers", Aliment Pharmacol Ther, 46, pp.599~604 (2017)
6. Cheng PN, "Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B", Aliment Pharmacol Ther, 59, pp.230~238 (2024)
7. Sun HY, "Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir", elbasvir or ledipasvir, Gut, pp.2018, 67[DOI]
8. Hong H, "Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide", Clin Mol Hepatol, 30, pp.49~63 (2024)

관련 논문AI추천